Past catalysts on this ticker, reconciled against the announcement parse pipeline. Hover any row for the parsed outcome detail.
emu's own upcoming catalysts alongside class-defining historical readouts and upcoming primary completion dates in the same mechanism classes. Each event moves the broader thesis for emu. Showing past 6 months and next 12 months · 3 later hidden.
Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.
| Trial | Sponsor | Class | Phase / Line | Design | Primary endpoint | Dosing | Key eligibility | n |
|---|---|---|---|---|---|---|---|---|
| emu | Emvision Medical Devices | Microwave imaging device | Phase 3 | 0 | ||||
| EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF) | Population Health Research Institute | — |
Read-across commentary attached per trial. Phase ordering preserved within each group.
External analyst notes, journalism, and industry commentary cited with attribution.
"Sponsor guided" dates come from IR materials and earnings calls; hover for the cited source. "CT.gov proxy" dates fall back to the registry primary completion date — actual readouts typically follow by 3-6 months.
| — |
| — |
| — |
| — |
| — |
| Intracranial Hemorrhage Risk of Intensive Statin in Acute Ischemic Stroke With Cerebral Microbleeds | Sichuan Provincial People's Hospital | — | Phase 4 | — | — | — | — | — |
| Oral Hygiene and Prophylactic Antibiotics to Prevent Intracerebral Hemorrhage Associated Pneumonia | Beijing Tiantan Hospital | — | Phase 4 | — | — | — | — | — |
| Safety and Feasibility of Using Cerebrolysin in the Treatment of Primary Intracerebral Hemorrhage - a Prospective Randomized Open Blinded End-point Trial | Cardinal Stefan Wyszynski University | — | Phase 4 | — | — | — | — | — |
| International Care Bundle Evaluation in Cerebral Hemorrhage Research | Region Skane | — | Phase 4 | — | — | — | — | — |
| Anticoagulation in ICH Survivors for Stroke Prevention and Recovery | Yale University | — | Phase 3 | — | — | — | — | — |
| Stroke Prophylaxis With Apixaban in Chronic Kidney Disease Stage 5 Patients With Atrial Fibrillation | Region Stockholm | — | Phase 3 | — | — | — | — | — |
| Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial | Joseph Broderick, MD | — | Phase 3 | — | — | — | — | — |
| The Fifth INTEnsive pReventing Secondary Injury in Acute Cerebral Haemorrhage Trial Within ACT-GLOBAL | The George Institute | — | Phase 3 | — | — | — | — | — |
| Colchicine for the Reduction of Dependency and Vascular Events After an Acute Intracerebral Hemorrhage | Population Health Research Institute | — | Phase 3 | — | — | — | — | — |
| Thrombolysis in Factor Xa-inhibitors Trial | Guri Hagberg | — | Phase 3 | — | — | — | — | — |
| Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2 | Joseph Broderick, MD | — | Phase 3 | — | — | — | — | — |
| Reducing the Burden of Cardiovascular Events With Antiplatelet Therapy in Patients With IntraCerebral Haemorrhage | Christian Medical College and Hospital, Ludhiana, India | — | Phase 3 | — | — | — | — | — |
| ACT-GLOBAL Adaptive Platform Trial for Stroke | The George Institute | — | Phase 3 | — | — | — | — | — |
| Minocycline in Stroke Study at Maimonides | Joyce Chen | — | PHASE2/PHASE3 | — | — | — | — | — |
| Hemorrhagic Brainstem Cavernous Malformations Treatment With Sirolimus: aSingle Centre, Randomized, Placebo-controlled Pilot Trial | Huashan Hospital | — | Phase 2 | — | — | — | — | — |
| Regulating Blood Pressure During Recovery From Intracerebral Hemorrhage and Ischemic Stroke | Yale University | — | Phase 2 | — | — | — | — | — |
| A Study to Evaluate the Safety, Tolerability and the Effects of Ixodes Ricinus-Contact Phase Inhibitor (Ir-CPI) in Adult Patients With Spontaneous Intracerebral Haemorrhage | Bioxodes S.A. | — | Phase 2 | — | — | — | — | — |
| Intra-Arterial Tenecteplase Following Endovascular Thrombectomy for Large Vessel Occlusion Stroke | Wake Forest University Health Sciences | — | Phase 2 | — | — | — | — | — |
| Study of BB-031 in Acute Ischemic Stroke Patients (RAISE) | Basking Biosciences, Inc. | — | Phase 2 | — | — | — | — | — |
| Effect of Xenon on Brain Injury After Aneurysmal Subarachnoid Hemorrhage | Turku University Hospital | — | Phase 2 | — | — | — | — | — |